Financials data is unavailable for this security.
View more
Year on year Simcere Pharmaceutical Group Ltd had net income fall -23.22% from 930.87m to 714.76m despite a 4.49% increase in revenues from 6.32bn to 6.61bn. An increase in the cost of goods sold as a percentage of sales from 20.99% to 24.57% was a component in the falling net income despite rising revenues.
| Gross margin | 77.02% |
|---|---|
| Net profit margin | -17.40% |
| Operating margin | -17.47% |
| Return on assets | -9.04% |
|---|---|
| Return on equity | -13.82% |
| Return on investment | -11.71% |
More ▼
Cash flow in CNYView more
In 2023, Simcere Pharmaceutical Group Ltd increased its cash reserves by 21.04%, or 348.85m. Cash Flow from Investing totalled 1.09bn, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company generated 151.05m in cash from operations while cash used for financing totalled 894.83m.
| Cash flow per share | -0.3266 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 2.92 |
|---|---|
| Tangible book value per share | 2.45 |
More ▼
Balance sheet in CNYView more
| Current ratio | 2.10 |
|---|---|
| Quick ratio | 1.88 |
| Total debt/total equity | 0.1711 |
|---|---|
| Total debt/total capital | 0.1461 |
More ▼
Growth rates in CNY
Year on year, growth in dividends per share increased 2.89% while earnings per share excluding extraordinary items fell by -22.87%. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
| EPS growth(5 years) | -2.62 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -135.26 |
